Loading
Consolidation Immunotherapy / Radiotherapy Or Sequential Chemoradiation / Tislelizumab · Phase 2 Trial
ClinicalTrials.gov · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 trial registration studying tislelizumab consolidation after radiotherapy or sequential chemoradiation in locally advanced NSCLC patients intolerant of concurrent chemoradiation. No results have been posted in this registry record, so no efficacy or safety data are available for appraisal.
Phase 2, Interventional, Single Group, Open label, Treatment purpose. Non-small Cell Lung Cancer, Consolidation Immunotherapy, Radiotherapy or Sequential Chemoradiation; age from 18 Years. Intervention: Consolidation Tislelizumab. n = 5. 1 site: China.
This is a Phase 2 trial registration studying tislelizumab consolidation after radiotherapy or sequential chemoradiation in locally advanced NSCLC patients intolerant of concurrent chemoradiation. No results have been posted in this registry record, so no efficacy or safety data are available for appraisal.
Results not yet posted in registry record; no efficacy, safety, or outcome data reported.
No clinical impact can be assessed from this registry record because results are not posted. Clinicians awaiting data on tislelizumab consolidation in chemoradiation-intolerant patients should monitor for publication of this trial's findings.
Phase 2 trial with minimal enrollment (5 participants) in a population intolerant of concurrent chemoradiation; no results are posted in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
No clinical impact can be assessed from this registry record because results are not posted. Clinicians awaiting data on tislelizumab consolidation in chemoradiation-intolerant patients should monitor for publication of this trial's findings.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05758116). This is a study registration, not published results. Lead sponsor: Peking University Cancer Hospital & Institute. Recruitment status: COMPLETED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 5 participants (ACTUAL). Conditions: Non-small Cell Lung Cancer, Consolidation Immunotherapy, Radiotherapy or Sequential Chemoradiation. Interventions: DRUG: Tislelizumab. Primary outcome measures: Progression-free survival , 6 months after enrollment. Brief summary: The current standard of care for locally advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiation and consolidation immunotherapy. In real world clinical practice, patients who cannot tolerate concurrent chemoradiation generally received radiotherapy alone or sequential chemoradiation. These patients are more likely to develop distant metastases and therefore may require tolerable systemic consolidation regimens. However, there is a lack of evidence from clinical studies on consolidation immunotherapy after radiotherapy alone or sequential chemoradiation. The aim of the study is to explore the efficacy and safety of Tislelizumab consolidation therapy after radiotherapy or sequential chemoradiation in locally advanced NSCLC patients who are intolerable of concurrent concurrent chemoradiation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.